Sign In
Buy BIIB
$207.94
+1.66 (+0.80%)
At Close: Aug 07, 2026
Biogen's stock slides premarket as analysts take mixed view of Alzheimer's disease drug approval
07:29am, Friday, 07'th Jul 2023
Biogen Inc.'s stock BIIB, -0.31% rose about 2% before paring those gains premarket Friday, after the U.S. Food and Drug Administration on Thursday granted full approval to Leqembi, the company's Alzhe
Alzheimer's drug, the first to slow disease progression, gets FDA green light
02:58am, Friday, 07'th Jul 2023
Eisai, a Japanese firm, and American drugs giant Biogen Inc (NASDAQ:BIIB) have received full Food & Drug Administration approval for Leqembi, a groundbreaking drug that curbs Alzheimer's disease progr
FDA Approves Leqembi, Extending Alzheimer's Treatment to More Patients
06:57pm, Thursday, 06'th Jul 2023
Medicare enrollees can get the anti-amyloid treatment as a result of the agency's full approval.
First drug to slow progression of Alzheimer's disease approved in US
06:44pm, Thursday, 06'th Jul 2023
The US Food and Drug Administration (FDA) has fully approved a drug that slows the progression of Alzheimer's disease for the first time.
FDA Grants Full Approval For Alzheimer's Drug, Despite Concerns
05:30pm, Thursday, 06'th Jul 2023
Leqembi costs $26,000 per year before insurance.
FDA approves Alzheimer's drug Leqembi, paving way for broader Medicare coverage
05:22pm, Thursday, 06'th Jul 2023
'Closing Bell Overtime' breaks latest from the FDA concerning Biogen's Alzheimer's drug.
FDA approves Biogen and Eisai Alzheimer's treatment Leqembi
04:55pm, Thursday, 06'th Jul 2023
The U.S. Food and Drug Administration on Thursday granted full approval to the Biogen BIIB and Eisai Co. Ltd. ESALF Alzheimer's treatment Leqembi, a step that secures Medicare reimbursement for the fi
FDA approves Alzheimer's drug Leqembi, paving way for broader Medicare coverage
04:44pm, Thursday, 06'th Jul 2023
Leqembi slowed cognitive decline in a clinical trial, but the treatment is expensive and carries serious risks of brain swelling and bleeding.
U.S. Wide-Moat Stocks On Sale - The July 2023 Heat Map
09:31am, Thursday, 06'th Jul 2023
Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of th
Is This a Sign That Biogen's Leqembi Could Obtain FDA Approval Next Month?
07:30am, Friday, 23'rd Jun 2023
The FDA could soon make a decision on Biogen's Alzheimer's drug, Leqembi. An advisory committee confirmed its clinical benefits, suggesting an approval could be ahead.
Does This Signal Trouble for Biogen's New Alzheimer's Drug?
05:30am, Monday, 19'th Jun 2023
Some European Alzheimer's experts are wary about the future of Biogen's drug Leqembi in the region. Regulators in Europe, the U.S., and Japan currently are reviewing the drug.
2 Market-Beating Stocks With Major Catalysts on the Way
10:07am, Saturday, 17'th Jun 2023
Vertex's next blockbuster could generate billions of dollars in sales. Biogen is inching closer to a goal it's been working on for a long time.
7 Undervalued S&P 500 Stocks to Buy in June
09:35pm, Thursday, 15'th Jun 2023
When attempting to build a portfolio of reliable entities, you probably can't go wrong with undervalued S&P 500 stocks. Featuring the market performance of 500 of the largest companies listed on stock
What's Happening With Biogen Stock?
08:00am, Wednesday, 14'th Jun 2023
After a 13% rise in Biogen stock (NASDAQ: BIIB) this year, aligning with the broader S&P500 index returns, we believe it has little room for growth.
Biogen has been an 'uninvestable' stock for awhile, says Mizuho's Jared Holz
06:36pm, Tuesday, 13'th Jun 2023
Jared Holz, Mizuho Securities healthcare sector specialist, joins 'Fast Money' to talk controversy brewing at Biogen, Alzheimer's drug approval roadblocks in Europe, and more.
